Specialty Pharmaceuticals and Patient Privacy
In the specialty pharmaceutical industry, patient privacy is crucial. Privacy can be a challenge for companies looking to gather and consolidate patient information from various sources. The de-identification of that information is critical to unlocking the ability to use this data to make smarter business decisions and enhance drug development.
De-identifying data can provide pharmaceutical companies with a variety of benefits, including:
Read our white paper to learn how de-identifying data can help biopharmaceutical companies tap into the broad base of evidence required to support and grow business, while maintaining patient privacy.
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.